Prostate cancer: 10. Palliative care

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 3, 1999, Pages 365-371

  Iscoe, Neill A ^a,d   Bruera, Eduardo ^b   Choo, Richard C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYTOTOXIC AGENT; PROSTATE SPECIFIC ANTIGEN;

AGED; ALTERNATIVE MEDICINE; ARTICLE; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CASE REPORT; HUMAN; MALE; ORCHIECTOMY; PAIN; PROSTATE CANCER; RELAPSE; TEA;

EID: 0033537478     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Office of Technology Assessment. Unconventional cancer treatments. Washington: United States Government Printing Office; 1990. Rep no OTA-H-405.
2. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 1998;280:1569-75.
3. Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre. How to read clinical journals: IV. To determine etiology or causation. CMAJ 1981;124:985-90.
4. Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre. How to read clinical journals: V. To distinguish useful from useless or even harmful therapy. CMAJ 1981;124:1156-62.
5. Fontanarosa PB, Lundberg GD. Alternative medicine meets science [editorial]. JAMA 1998;280:1618-9.
6. Cole DJ. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol 1989;1:59-62.
7. Madsen EL. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys 1983;9:1775-9.
8. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986;6:247-55.
9. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
10. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985;55:1468-72.
11. Arcangeli G, Micheli A, Arcangeli G, Giannarelli D, La Pasta O, Tollis A, et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989;14:95-101.
12. Fitzpatrick PJ, Rider WD. Half-body radiotherapy. Int J Radiat Oncol Biol Phys 1976;1:197-207.
13. Salazar OM, Rubin P, Hendrickson FR, Poulter C, Zagars G, Feldman MI, et al. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys 1981;7:773-81.
14. Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys 1989;17:1281-5.
15. Ben-Josef E, Lucas DR, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation. Nucl Med Commun 1995;16:457-63.
16. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
17. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomized double-blind crossover study to examine the efficacy, of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954-8.
18. Buchali K, Correns HJ, Schuerer M, Schnoor D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14:349-51.
19. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DC, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
20. Porter AT, Ben-J̀osef E. Strontium 89 in the treatment of bone metastases. In: DeVita VT, Helman S, Rosenberg SA, editors, Important advances in oncology. Philadelphia: JB Lippincott; 1995. p. 87-94.
21. Zelefsky JM, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Spinal epidural tumor in patients with prostate cancer. Cancer 1992;70:2319-25.
22. Management of cancer pain: clinical practice guidelines. Rockville (MD): Agency for Health Care Policy and Research, Department of Health and Human Services; 1994. AHCPR publ 94-0592.
23. Bruera E, Valasco-Leiva A, Spachynski K, Fainsinger R, Miller MJ, MacEachern T. The use of the Edmonton Injector (EI) for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain Symptom Manage 1993;8:525-8.
24. Bloomfield DJ. Should bisphosphonates be part of standard therapy of patients with multiple myeloma and bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998;16:1218-26.
25. Ernst DS, Brasher P, Hagen N, Paterson AHG., MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26.
26. Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Suarez-Almazor M, et al. A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage 1995;10:348-55.
27. Fainsinger R. Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson L, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford University Press; 1996. p. 128-40.
28. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997;79:835-42.
29. Ripamonti C, Bruera E. CNS adverse effects of opioids in cancer patients. Guidelines for treatment. Cent Nerv Syst Drugs 1997;8:21-37.